Sam Mintz
Odyssey Therapeutics, launched early in 2021 by serial biotech entrepreneur Gary Glick, has brought in a big Series A round and is differentiating itself with what Glick calls “intellectual capital.” The company is working on a broad array of ailments, developing protein therapeutics and small molecules to modulate the immune system, with the goal of tackling inflammatory disorders, autoimmune diseases and oncology. It’s got a star-studded team of senior leaders and scientists, many of them pulled from big pharma.